ESMO 2023 Bladder Cancer

Viewing 1-20 of 39 articles

ESMO 2023: Global Access Considerations in Systemic Treatment of Genitourinary Cancers

ESMO 2023: State-of-the-Art in Adjuvant Treatment of Urothelial Cancer

ESMO 2023: Current Peri-Operative Trial Designs and Endpoints: What Do They Mean?

ESMO 2023: Antibody Drug Conjugates and FGFR-Directed Therapies: New Toxicities

ESMO 2023: Screening New Agents in “Window of Opportunity” Neoadjuvant Trials

ESMO 2023: Discussant: TAR-210 & SunRISe-1

ESMO 2023: Discussant – ABACUS-2, NEMIO, EV-103 (Cohort-L)

ESMO 2023: TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–Muscle-Invasive Bladder Cancer with Select FGFR Alterations: First Safety and Efficacy Results

ESMO 2023: SunRISe-1: TAR-200 Monotherapy in Patients With BCG Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer (HR NMIBC)

ESMO 2023: EV-103 Cohort L: Perioperative Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer

ESMO 2023: ABACUS-2, A Phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Non-Urothelial Muscle Invasive Bladder Cancer

ESMO 2023: NEMIO, a Randomized Phase I-II Trial: Durvalumab +/- Tremelimumab in Combination with Dose-Dense MVAC as Neoadjuvant Treatment in Patients with Muscle-Invasive Bladder Carcinoma

ESMO 2023: Discussant: EV-302/KEYNOTE-A39 & CheckMate 901: Welcoming a New Standard of Care in the First-Line Treatment of Urothelial Carcinoma

ESMO 2023: Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Treatment Patterns and Real-World Outcomes in the US

ESMO 2023: CheckMate 901: Nivolumab plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone for Previously Untreated Unresectable or Metastatic Urothelial Carcinoma: Phase 3 Results

ESMO 2023: Invited Discussant – PET-MUSE and the Phase 3 THOR Study

ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma

ESMO 2023: AVENANCE: Subgroup Analysis of Patients with Advanced Urothelial Carcinoma with Histological Variants from a Real-World Study of Avelumab First-Line

ESMO 2023: Real World Effectiveness of Single Agent Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Based on Line of Therapy and Impact of Prior Platinum Chemotherapy and PD-1/PD-L1 Inhibitors

ESMO 2023: Erdafitinib vs Chemotherapy in Patients With Advanced or Metastatic Urothelial Cancer With Select FGFR Alterations: Subgroups From the Phase 3 THOR Study

1
2